Anti-b7s1 polypeptides and their use
AssigneesSuzhou Kanova Biopharmaceutical Co., Ltd., Beijing Kanova Biopharmaceutical Co., Ltd.
InventorsLi GUO, Tiantian SUN, Nidan WANG, Chen DONG
Life of this patent
Estimating the term…
Abstract
The present invention is related to anti-B7S1 (B7-H4) polypeptides including anti-B7S1 (B7-H4) antibodies and their immunoreactive fragments, chimeric antigen receptor (CAR) binding to B7S1 (B7-H4) molecule and the uses thereof, particularly in the treatment of cancers. The invention particularly concerns humanized anti-B7S1 antibodies and their antigen binding fragments capable of enhancing the activation of the immune system against diseased tissues including cancerous cells, and the genetically engineered immune cells expressing anti-B7S1 CAR used for treatment of diseases including cancers.
Claims23
An isolated antibody or antigen binding fragment thereof, comprising a heavy chain (HC) variable region sequence and a light chain (LC) variable region sequence, wherein the antibody binds to an extracellular domain of B7S1 with a binding affinity of about 1-4 nM as determined by SPR analysis.
(canceled)
21-22. (canceled)
24-26. (canceled)
Dependencies are inferred from the claim text.